GovChime
Notice ID: 49e123ce2cd844449f09820f7b1c9ac1Special Notice

TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform

Active, responses due . Full description on SAM.gov.

Overview

Response deadline
5:00 PM MST
Posted
June 4, 2026
Notice type
Special Notice
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Energy

Notice details

Office
TRIAD - DOE CONTRACTOR
Place of performance
Los Alamos, New Mexico, 87545
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
S-195396
Notice ID
49e123ce2cd844449f09820f7b1c9ac1

Description

This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations.

The Opportunity:

Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatment modalities. By enabling more precise control over where and how therapeutic gases are delivered, the platform has the potential to unlock new product categories, enhance combination treatment strategies and accelerate translation of gas-based therapeutics into high-value clinical markets.

How it Works:

The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies.

Key Advantages:

  • Localized delivery: Targets therapeutic gases to the intended site while minimizing systemic exposure.
  • Controlled release: Designed for sustained, tunable dosing under physiological conditions.
  • Improved safety margin: Aims to separate therapeutic effect from toxicity risk.
  • Platform versatility: Applicable across oncology, cardiovascular, neurological and regenerative indications.
  • Development optimization: Supported by predictive modeling to guide dose and design decisions.
  • Partnership-ready architecture: Suitable for integration with drug-device combinations and existing treatment modalities.

Market Applications:

  • Oncology Therapeutics Industry
  • Cardiovascular and Vascular Medicine Industry
  • Neurology and Neurodegenerative Disease Sector
  • Regenerative Medicine and Tissue Engineering Industry
  • Medical Device and Drug-Device Combination Companies
  • Biotechnology and Specialty Pharma Companies
  • Computational Drug Development and Modeling Firms

Development Status: TRL 2

US patent pending

LA-UR-26-22810

LANL Tech Partnerships: Unlock the Innovative Potential

Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.

LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov.

Note: This is not a call for external services for the development of this technology.

https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology

m.lanl.gov/tech-search

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Caleb Ledgerwood

Secondary Contact

Lindsay Augustyn

Documents

No documents available.

Lifecycle

  1. 1
    Version 1Special NoticeCurrent

    TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform

    Notice 49e123ce2cd844449f09820f7b1c9ac1 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient, and less damaging. The Challenge: Purifying antibodies — vital tools in medicine and research — typically relies on a protein called Protein G that latches onto them. However, getting the antibodies back off this molecular “magnet” requires very acidic conditions, which can damage both the antibodies and Protein G itself. This harsh process risks ruining expensive materials and reducing the effectiveness of critical therapies and tests. Problems Solved: Researchers engineered a pH-switchable version of Protein G that uses gentle changes in acidity (pH) to control when it releases antibodies, it now binds antibodies at a mildly acidic pH and releases at a mildly basic pH — eliminating the need for harsh chemicals. This innovation protects sensitive proteins, improves efficiency, lowers costs, and opens the door for safer, greener, and more effective antibody purification in both labs and industry. Key Advantages: Gentle elution conditions: Antibodies are released at a mild pH (~8.2) instead of harsh acidic conditions (~2.7), reducing damage to both the antibodies and the protein itself. Improved antibody stability and yield: Preserving antibody structure increases reliability and effectiveness, which is especially critical for therapeutic and diagnostic use. Switchable binding mechanism: pH-sensitive histidine residues allow for a controlled "on/off" switch based on pH, improving process control and reproducibility. Cost-effective and scalable: Reduces loss of expensive antibodies and minimizes the need for post-purification repair or replacement, saving money in industrial applications. Market Applications: Biopharmaceuticals Life Sciences Research Bioprocessing and Manufacturing Tools Veterinary and Agricultural Biotech Development Status: TRL 4 US Provisional / Patent No. 10,954,275 LA-UR-25-29451 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
-Special Notice12/05/2025
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
-Market Research11/15/2026
Please see attached for the sources sought notice/market research survey and MPID.
-Market Research11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation10/26/2026
A Capacity Indicator for Hydrogen Getters Imagine a hydrogen getter that tells you how much protective life it has left, simply by changing color, so engineers can read remaining capacity at a glance without ever opening the sealed device it guards. GetterGauge pairs that built-in gauge with a level of selectivity most getters cannot match, pulling hydrogen out of a sealed space while ignoring the helium, nitrogen, argon and methane around it and continuing to work. even at pressures a thousand times below atmospheric. Underpinning the color-change readout is a material that holds up to roughly three times more hydrogen than fielded products, works from below freezing to well above the boiling point of water, and needs no activation step before use. Because the material is friendly to plastics and polymers, it can be shaped to fit the device rather than forcing the device to fit the getter, opening the door to smaller, longer-lived and lower-cost sealed systems across electronics, medicine, aerospace and energy. Challenges Sealed and vacuum systems fail early when hydrogen accumulates inside them, because hydrogen corrodes metals, embrittles structural parts and can build toward a dangerous release. Getters exist to prevent that outcome, yet the versions on the market carry a stubborn set of limitations: The best ones store only about 350 cubic centimeters of hydrogen per gram, perform within a narrow temperature window, generally demand a separate activation step, lack selectivity against background gases and cost more than product designers would like. A second, quieter problem compounds the first: Once a getter is sealed inside a satellite, implant or waste container, there has been no non-destructive way to learn how much hydrogen it has already taken up. Engineers are left to guess at remaining protection, which forces a hard trade between replacing parts early on a cautious schedule and risking a silent loss of protection, and both choices add cost and uncertainty to equipment that is expensive to build and hard to reach. Problems Solved This new getter family answers the capacity and performance limits directly. Storage rises to as much as 1200 cubic centimeters per gram. The operating range widens to span below 0 through above 100 degrees Celsius. The materials capture hydrogen at very low pressures, thousands of times lower than the atmosphere pressure, without the customary activation step. Hydrogen is taken up selectively, even when helium, nitrogen, argon or methane is present and while allowing the uptake rate to be dialed in through catalyst loading. The feature that sets these getters apart, however, speaks straight to the inspection gap: A colorimetric response turns the material itself into a gauge, changing color or brightening as it absorbs hydrogen so that remaining capacity can be read visually and without destroying the part. A getter that reports its own remaining life converts the old guessing game into a simple visual check, letting operators retire a part when it is genuinely spent rather than on a conservative calendar. Advantages Reports its own remaining capacity through a simple, non-destructive color change, with no need to open or sacrifice the sealed part Turns replacement from a cautious calendar guess into a visual check, so parts are retired only when genuinely spent Delivers strong core performance in one package; up to roughly three times the hydrogen of conventional getters, a wide temperature range and no activation Captures hydrogen selectively at pressures far below atmospheric, ignoring helium, nitrogen, argon and methane Allows designers to tune the capture rate by adjusting catalyst loading to match the application Blends into plastics and polymers for flexible shapes and smaller footprints Market Applications Nuclear Industry (tritium and deuterium capture and storage, waste containers, handling gloveboxes) Microelectronics and Semiconductors (sealed and hermetic device packaging, vacuum components) Aerospace and Space Systems (satellites) Medical Devices (implantable devices) Scientific and Medical Imaging Equipment (X-ray tubes, particle accelerators) Thermal Insulation and Energy Efficiency (vacuum-insulated panels and devices) TRL 4 LA-UR-26-28528 U.S. Patent pending LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search
-Special Notice03/05/2027

Additional Details

Solicitation Number

S-195396

Archive Date

Jun 30, 2027

Office Address

Columbus, OH, 43201